Search research articles
Contact Us
Filters
Showing results (21-30 of 37) with videos related to
Page
of 4
Sort By:
SLAS Discovery : Advancing Life Sciences R & D
|
July 22, 2017
Identification of SPPL2a Inhibitors by Multiparametric Analysis of a High-Content Ultra-High-Throughput Screen
Xian Zhang, Marjo Götte, Yvonne Ibig-Rehm, et al.
ACS Infectious Diseases
|
January 18, 2018
Development of a Cytopathic Effect-Based Phenotypic Screening Assay against Cryptosporidium
Alexander T Chao, Boon Heng Lee, Kah Fei Wan, et al.
Antimicrobial Agents and Chemotherapy
|
March 14, 2018
Imidazolopiperazines Kill both Rings and Dormant Rings in Wild-Type and K13 Artemisinin-Resistant Plasmodium falciparum In Vitro
Laurent Dembele, Devendra Kumar Gupta, Michelle Yi-Xiu Lim, et al.
Plos One
|
January 10, 2013
FGFR2 promotes breast tumorigenicity through maintenance of breast tumor-initiating cells
Sungeun Kim, Anna Dubrovska, Richard J Salamone, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 21, 2017
Discovery of 2-oxopiperazine dengue inhibitors by scaffold morphing of a phenotypic high-throughput screening hit
Cyrille S Kounde, Hui-Quan Yeo, Qing-Yin Wang, et al.
ACS Chemical Biology
|
August 27, 2011
A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor
Tae-Gyu Nam, Case W McNamara, Selina Bopp, et al.
Cell Reports
|
April 20, 2017
The Natural Product Cavinafungin Selectively Interferes with Zika and Dengue Virus Replication by Inhibition of the Host Signal Peptidase
David Estoppey, Chia Min Lee, Marco Janoschke, et al.
Scientific Reports
|
May 26, 2017
The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites
L Dembele, X Ang, M Chavchich, et al.
Cell Host & Microbe
|
March 20, 2012
Cofactors required for TLR7- and TLR9-dependent innate immune responses
Chih-Yuan Chiang, Alex Engel, Amanda M Opaluch, et al.
JAMA Oncology
|
March 3, 2022
Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial
Xavier Pivot, M A Georgievich, Volodymyr Shamrai, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 37) with videos related to
Sort By:
Page
of 4
SLAS Discovery : Advancing Life Sciences R & D
|
July 22, 2017
Identification of SPPL2a Inhibitors by Multiparametric Analysis of a High-Content Ultra-High-Throughput Screen
Xian Zhang, Marjo Götte, Yvonne Ibig-Rehm, et al.
ACS Infectious Diseases
|
January 18, 2018
Development of a Cytopathic Effect-Based Phenotypic Screening Assay against Cryptosporidium
Alexander T Chao, Boon Heng Lee, Kah Fei Wan, et al.
Antimicrobial Agents and Chemotherapy
|
March 14, 2018
Imidazolopiperazines Kill both Rings and Dormant Rings in Wild-Type and K13 Artemisinin-Resistant Plasmodium falciparum In Vitro
Laurent Dembele, Devendra Kumar Gupta, Michelle Yi-Xiu Lim, et al.
Plos One
|
January 10, 2013
FGFR2 promotes breast tumorigenicity through maintenance of breast tumor-initiating cells
Sungeun Kim, Anna Dubrovska, Richard J Salamone, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 21, 2017
Discovery of 2-oxopiperazine dengue inhibitors by scaffold morphing of a phenotypic high-throughput screening hit
Cyrille S Kounde, Hui-Quan Yeo, Qing-Yin Wang, et al.
ACS Chemical Biology
|
August 27, 2011
A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor
Tae-Gyu Nam, Case W McNamara, Selina Bopp, et al.
Cell Reports
|
April 20, 2017
The Natural Product Cavinafungin Selectively Interferes with Zika and Dengue Virus Replication by Inhibition of the Host Signal Peptidase
David Estoppey, Chia Min Lee, Marco Janoschke, et al.
Scientific Reports
|
May 26, 2017
The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites
L Dembele, X Ang, M Chavchich, et al.
Cell Host & Microbe
|
March 20, 2012
Cofactors required for TLR7- and TLR9-dependent innate immune responses
Chih-Yuan Chiang, Alex Engel, Amanda M Opaluch, et al.
JAMA Oncology
|
March 3, 2022
Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial
Xavier Pivot, M A Georgievich, Volodymyr Shamrai, et al.
Page
of 4